Protek Group announces financial results for 1HY-2017

25.08.2017

Protek Group (PRTK:RTS, MICEX), one of the major pharmaceutical companies in Russia operating in all segments of the Russian pharmaceutical market (production, distribution and retail sales), announces it’s PwC reviewed IFRS results for 1HY-2017.

In 1HY-2017, the Group’s consolidated revenue went up by 11.9% y-o-y to RUB 123,287 mln.

The Group made a consolidated gross profit of RUB 15,695 mln, driving the gross margin to 12.7%.

The Group’s consolidated EBITDA amounted to RUB 5,328 mln, with EBITDA margin of 4.3%.

Financial Highlights of the Group and segments, 1HY-2017:

Revenue, RUB mln.

Gross profit, RUB mln.

Gross margin, %

EBITDA, RUB mln.

EBITDA margin, %

GROUP

123,287

15,695

12.7%

5,328

4.3%

Distribution

104,237

5,966

5.7%

2,426

2.3%

Retail

23,802

6,420

27.0%

1,065

4.5%

Production

5,738

3,322

57.9%

1,940

33.8%

Financial Highlights of the Group and segments, 1HY-2016:

Revenue,   RUB mln.

Gross profit,   RUB mln.

Gross margin, %

EBITDA,     RUB mln.

EBITDA margin, %

GROUP

110,176

13,823

12.5%

5,045

4.6%

Distribution

95,811

5,888

6.1%

2,684

2.8%

Retail

18,122

5,088

28.1%

770

4.2%

Production

5,007

2,903

58.0%

1,728

34.5%

“Group's consolidated revenue growth rate accounted to 11.9% while Russian pharmaceutical market showed growth of 13.3% in value terms and 13.0% in packages*. Revenue of Distribution segment grew by 8.8% primarily due to the growth in commercial market sales. Production segment’s revenue increased by 14.6% y-o-y, this was determined by a bigger input of proprietary brands in revenue. Revenue growth rate of Retail segment of 31.3% was due to an active development of the private labels and a growing number of pharmacies in the retail chain (+13%). Overall, the management of PROTEK Group is reasonably satisfied with Group results of 1HY-2017” – has commented on the 1HY-2017 financial results Mr. Vadim Muzyaev, President of PROTEK Group.

*According to DSM Group

News list
сотексРафармапротеинпротектранссервис
Проаптекаспаргопротек-свмриглапротек фонд